Letrozone AlphaZone Pharmaceuticals: Compound Profile
Letrozone by AlphaZone Pharmaceuticals is a third-generation aromatase inhibitor compound containing letrozole as its active pharmaceutical ingredient. Letrozole functions as a competitive inhibitor of the aromatase enzyme (CYP19A1), which catalyses the conversion of androgens to estrogens in peripheral tissues. This mechanism makes it a valuable research tool for investigating estrogen biosynthesis pathways and hormonal regulation studies. Researchers at Stroid UK Shop frequently utilise this compound alongside other research chemicals from our extensive catalogue including SARMs and peptides for comprehensive endocrine research protocols.
Laboratory Applications
In research settings, letrozole demonstrates potent aromatase inhibition with IC50 values in the nanomolar range across various tissue types. Studies examine its effects on estradiol and estrone synthesis in cell culture models, particularly in breast cancer research where aromatase expression correlates with tumor progression. The compound’s selectivity profile shows minimal interaction with other steroidogenic enzymes at therapeutic concentrations, making it useful for isolating aromatase-specific pathways. Researchers investigate letrozole’s pharmacokinetic properties, including its extensive hepatic metabolism via CYP3A4 and CYP2A6 pathways. Comparative studies with other aromatase inhibitors evaluate relative potency, reversibility, and tissue distribution characteristics in preclinical models.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Letrozole |
| CAS Number | 112809-51-5 |
| Molecular Formula | C₁₇H₁₁N₅ |
| Molecular Weight | 285.30 g/mol |
| Manufacturer | AlphaZone Pharmaceuticals |
| Product Code | EU24167 |
| Storage Conditions | Room temperature, dry environment |
| Solubility | DMSO, ethanol, limited water solubility |
Research Compliance Statement
Letrozone is manufactured by AlphaZone Pharmaceuticals exclusively for laboratory research purposes and in-vitro applications. This product is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure compliance with local regulations governing the handling and study of aromatase inhibitor compounds. All experimental protocols should include appropriate safety measures and waste disposal procedures. Purchase and use of this compound should be restricted to qualified research institutions and licensed laboratories conducting legitimate scientific investigations into estrogen biosynthesis and related biochemical pathways.
